| Literature DB >> 34007270 |
Yamini Subramani1, Omar El Tohamy2, Daniil Jalali2, Mahesh Nagappa1, Homer Yang1, Ashraf Fayad1.
Abstract
BACKGROUND: Atrial fibrillation (AF) occurs in 16-30% of patients after cardiac and thoracic surgery and can lead to serious complications like hypoperfusion of vital organs, pulmonary edema, and myocardial infarction. The evidence on risk factors and complications associated with perioperative AF after noncardiothoracic surgery is limited.Entities:
Year: 2021 PMID: 34007270 PMCID: PMC8099514 DOI: 10.1155/2021/5527199
Source DB: PubMed Journal: Anesthesiol Res Pract ISSN: 1687-6962
Figure 1PRISMA flow diagram showing the articles screened for eligibility as per the inclusion criteria to be included in the systematic review and meta-analyses.
Figure 2Forest plot evaluating age as a risk factor for perioperative atrial fibrillation in patients undergoing noncardiothoracic surgery. The mean difference of each included study is plotted. A pooled estimate of overall mean difference (diamonds) and 95% confidence intervals (width of diamonds) summarizes the effect size using the random effects model. CI = confidence interval; IV = inverse variance; MD = mean difference; I2: heterogeneity; P < 0.05 is significant.
Figure 3Forest plot evaluating male gender as a risk factor for perioperative atrial fibrillation in patients undergoing noncardiothoracic surgery. The odds ratio of each included study is plotted. A pooled estimate of overall odds ratio (diamonds) and 95% confidence intervals (width of diamonds) summarizes the effect size using the random effects model. CI = confidence interval; M–H = Mantel–Haenszel; OR = odds ratio; I2: heterogeneity; P < 0.05 is significant.
Figure 4Forest plot evaluating hypertension as a risk factor for perioperative atrial fibrillation in patients undergoing noncardiothoracic surgery. The odds ratio of each included study is plotted. A pooled estimate of overall odds ratio (diamonds) and 95% confidence intervals (width of diamonds) summarizes the effect size using the random effects model. CI = confidence interval; M–H = Mantel–Haenszel; OR = odds ratio; I2: heterogeneity; P < 0.05 is significant.
Figure 5Forest plot evaluating diabetes mellitus as a risk factor for perioperative atrial fibrillation in patients undergoing noncardiothoracic surgery. The odds ratio of each included study is plotted. A pooled estimate of overall odds ratio (diamonds) and 95% confidence intervals (width of diamonds) summarizes the effect size using the random effects model. CI = confidence interval; M–H = Mantel–Haenszel; OR = odds ratio; I2: heterogeneity; P < 0.05 is significant.
Figure 6Forest plot evaluating cardiac disease as a risk factor for perioperative atrial fibrillation in patients undergoing noncardiothoracic surgery. The odds ratio of each included study is plotted. A pooled estimate of overall odds ratio (diamonds) and 95% confidence intervals (width of diamonds) summarizes the effect size using the random effects model. CI = confidence interval; M–H = Mantel–Haenszel; OR = odds ratio; I2: heterogeneity; P < 0.05 is significant.
Figure 7Forest plot comparing cardiac complications between atrial fibrillation group and control groups in patients undergoing noncardiothoracic surgery. The odds ratio of each included study is plotted. A pooled estimate of overall odds ratio (diamonds) and 95% confidence intervals (width of diamonds) summarizes the effect size using the random effects model. CI = confidence interval; M–H = Mantel–Haenszel; OR = odds ratio; I2: heterogeneity; P < 0.05 is significant.
Figure 8Forest plot comparing mortality between atrial fibrillation group and control groups in patients undergoing noncardiothoracic surgery. The odds ratio of each included study is plotted. A pooled estimate of overall odds ratio (diamonds) and 95% confidence intervals (width of diamonds) summarizes the effect size using the random effects model. CI = confidence interval; M–H = Mantel–Haenszel; OR = odds ratio; I2: heterogeneity; P < 0.05 is significant.
Study quality assessment: meta-regression and sensitivity analysis of various subgroups (as categorical variable).
| Risk factor or outcome | Study characteristics (number of studies) | Summary estimate | 95% CI |
| Meta-regression | |
|---|---|---|---|---|---|---|
| Age | Coefficient (SE) |
| ||||
| Study type | Retrospective (9) [ | 3.75 | 0.75–6.76 | 90 | 0.6155 | 0.8651 |
| Prospective (2) [ | 5.03 | 2.97–7.09 | 0 | (3.6220) | ||
| Quality of study | Poor-moderate (1) [ | 14.34 | −11.37–40.05 | — | −0.3148 | 0.9486 |
| Good (10) [ | 3.97 | 1.57–6.38 | 89 | (4.8794) | ||
| Outcome defined | Yes (7) [ | 4.58 | 2.08–7.08 | 88 | 0.3634 | 0.9250 |
| No (4) [ | 3.12 | −4.31–10.55 | 83 | (3.8607) | ||
| Sample size >1000 | Yes (4) [ | 3.11 | −0.41–6.62 | 94 | 1.9924 | 0.4748 |
| No (7) [ | 4.93 | 1.51–8.34 | 67 | (2.7880) | ||
| Surgery type | Transplant (3) [ | 3.04 | −4.03–10.11 | 90 | −1.6709 | 0.6740 |
| Nontransplant (8) [ | 4.42 | 1.68–7.17 | 86 | (3.9716) | ||
|
| ||||||
| Gender | ||||||
| Study type | Retrospective (9) [ | 1.07 | 0.42–1.72 | 87 | −0.1621 | 0.8230 |
| Prospective (2) [ | 1.15 | 0.66–1.64 | 0 | (0.7248) | ||
| Quality of study | Poor-moderate (1) [ | 0.68 | −0.26–1.62 | — | −0.5386 | 0.5592 |
| Good (10) [ | 1.14 | 0.55–1.72 | 86 | (0.9223) | ||
| Outcome defined | Yes (7) [ | 1.43 | 1.33–1.52 | 0 | 0.4614 | 0.5366 |
| No (4) [ | 0.56 | −0.01–1.12 | 34 | (0.7465) | ||
| Sample size >1000 | Yes (4) [ | 1.07 | 0.29–1.86 | 95 | −0.3247 | 0.4981 |
| No (7) [ | 1.02 | 0.46–1.57 | 0 | (0.4793) | ||
| Surgery type | Transplant (3) [ | 0.80 | −0.04–1.63 | 83 | −0.3795 | 0.5944 |
| Nontransplant (8) [ | 1.43 | 1.33–1.53 | 0 | (0.7126) | ||
|
| ||||||
| Hypertension | ||||||
| Study type | Retrospective (8) [ | 1.15 | 1.07–1.22 | 0 | −0.1036 | 0.8490 |
| Prospective (2) [ | 1.24 | 0.75–1.74 | 0 | (0.5441) | ||
| Quality of study | Poor-moderate (0) | — | — | — | — | — |
| Good (10) [ | 1.15 | 1.08–1.23 | 0 | |||
| Outcome defined | Yes (7) [ | 1.15 | 1.08–1.23 | 0 | −0.8519 | 0.1879 |
| No (3) [ | 2.81 | −0.77–6.39 | 0 | (0.6469) | ||
| Sample size >1000 | Yes (4) [ | 1.15 | 1.08–1.23 | 0 | −0.2608 | 0.3738 |
| No (6) [ | 1.32 | 0.50–2.13 | 0 | (0.2933) | ||
| Surgery type | Transplant (3) [ | 1.24 | 0.74–1.75 | 0 | −0.0418 | 0.9409 |
| Nontransplant (7) [ | 1.15 | 1.07–1.23 | 0 | (0.5639) | ||
|
| ||||||
| Cardiac disease | ||||||
| Study type | Retrospective (7) [ | 2.79 | 0.17–5.41 | 92 | 1.3910 | 0.0545 |
| Prospective (2) [ | 1.32 | 0.16–2.49 | 55 | (0.7236) | ||
| Quality of study | Poor-moderate (0) | — | — | — | — | — |
| Good (9) [ | 2.30 | 0.28–4.31 | 93 | |||
| Outcome defined | Yes (6) [ | 2.15 | −0.16–4.46 | 95 | 0.0043 | 0.9956 |
| No (3) [ | 3.28 | −1.90–8.46 | 27 | (0.7790) | ||
| Sample size >1000 | Yes (3) [ | 3.86 | 0.90–6.82 | 92 | 0.7579 | 0.1808 |
| No (6) [ | 0.94 | 0.29–1.58 | 0 | (0.5663) | ||
| Surgery type | Transplant (3) [ | 2.94 | −0.63–6.52 | 13 | 0.9274 | 0.2304 |
| Nontransplant (6) [ | 2.01 | −0.42–4.44 | 96 | (0.7732) | ||
|
| ||||||
| Diabetes mellitus | ||||||
| Study type | Retrospective (8) [ | 0.97 | 0.89–1.05 | 0 | 0.7277 | 0.4019 |
| Prospective (1) [ | 0.61 | −0.70–1.92 | — | (0.8681) | ||
| Quality of study | Poor-moderate (0) | — | — | — | — | — |
| Good (9) [ | 0.97 | 0.89–1.05 | 0 | |||
| Outcome defined | Yes (6)[ | 0.97 | 0.89–1.05 | 0 | −0.2032 | 0.7579 |
| No (3)[ | 1.51 | 0.14–2.88 | 0 | (0.6595) | ||
| Sample size >1000 | Yes (3)[ | 0.97 | 0.89–1.05 | 0 | −0.2644 | 0.5052 |
| No (6) [ | 0.94 | 0.17–1.71 | 0 | (0.3968) | ||
| Surgery type | Transplant (2) [ | 1.48 | −0.51–3.48 | 0 | 0.3992 | 0.5901 |
| Nontransplant (7) [ | 0.97 | 0.89–1.05 | 0 | (0.7410) | ||
|
| ||||||
| Cardiac complications | ||||||
| Study type | Retrospective (5) [ | 5.71 | −0.18–11.61 | 83 | 0.3609 | 0.6949 |
| Prospective (1) [ | 4.34 | −1.11–9.79 | — | (0.9292) | ||
| Quality of study | Poor-moderate (0) | — | — | — | — | — |
| Good (6) [ | 5.44 | 0.49–10.39 | 82 | |||
| Outcome defined | Yes (5) [ | 5.41 | 0.36–10.46 | 85 | −0.7377 | 0.6474 |
| No (1) [ | 11.58 | −83.6–106.76 | 0 | (1.6127) | ||
| Sample size >1000 | Yes (1) [ | 10.51 | 9.63–11.39 | — | 0.9718 | 0.0023 |
| No (5) [ | 3.18 | 0.54–5.82 | 0 | (0.3193) | ||
| Surgery type | Transplant (1) [ | 11.58 | −83.60–106.76 | — | 0.7377 | 0.6474 |
| Nontransplant (5) [ | 5.41 | 0.36–10.46 | 85 | (1.6127) | ||
|
| ||||||
| Mortality | ||||||
| Study type | Retrospective (6) [ | 3.58 | 0.14–7.02 | 0 | — | — |
| Prospective (0) | — | — | — | |||
| Quality of study | Poor-moderate (1) [ | 2.47 | −22.62–27.56 | — | −0.7977 | 0.6530 |
| Good (5) [ | 3.60 | 0.13–7.08 | 0 | (1.7743) | ||
| Outcome defined | Yes (4) [ | 3.20 | −1.16–7.57 | 0 | 0.4607 | 0.6670 |
| No (2) [ | 4.21 | −1.39–9.81 | 0 | (1.0705) | ||
| Sample size >1000 | Yes (2) [ | 6.51 | −3.79–16.81 | 22 | 1.2296 | 0.0934 |
| No (4) [ | 2.69 | −1.67–7.06 | 0 | (0.7329) | ||
| Surgery type | Transplant (1) [ | 4.30 | −1.44–10.04 | — | −0.2072 | 0.8651 |
| Nontransplant (5) [ | 3.18 | −1.12–7.48 | 0 | (1.2196) | ||
Study quality scores were obtained from the Ottawa–Newcastle quality assessment [16]. Study was considered good when assigned score was equal 9. For respiratory complications and Stroke, meta-regression analysis not conducted due to inadequate number of studies.